Sharp Services, a provider of pharmaceutical packaging, clinical trial services and sterile manufacturing, is investing $100 million across its global facility network. With six GMP facilities in the U.S. and three in Europe, Sharp is expanding its services across its facility network to further extend its capabilities. 

Investments in Europe

The investment in new injectable capacity in the U.S. and Europe is in response to strong market demand for assembly and packaging of pre-filled syringes and autoinjectors, along with ancillary services. Sharp’s Netherlands facility is increasing GMP production capacity to accommodate new vial labeling, syringe assembly and injectables packaging, which is due to come online in 2026.  In Belgium, Sharp has begun a significant warehouse expansion which will include additional cold-chain and ambient storage and is building out a new syringe blistering production suite.

Investments in the U.S.

Additionally, Sharp’s Allentown campus will add a new pre-filled syringe assembly, labeling and packaging line, a vial labeler and high-speed cartoner, a mid-speed bottling and packaging line for OSD products, and automated pouch filling lines for powder and OSD products. This new equipment will add capacity to support exiting products as well as provide capacity for new opportunities.  

This follows the recent $20 million investment for autoinjector and pen assembly services at Macungie, PA. The plan includes installation of two autoinjector and pen assembly, labeling and packaging lines at its facility in Macungie.  

Sharp’s Bethlehem, PA, site which offers clinical services from preclinical through to commercial, began the installation of a 2-8 C production room with refrigerator and -15 C to -25 C walk-in freezer, two new capsule filling machines and an additional blister line to package OSD products. These new clinical and commercial capabilities will be operational at the site by end of 2025.

Sharp has also committed $28 million to significantly increase capacity at its sterile manufacturing facility in Lee, MA. The investment will support the installation of a fourth state-of-the-art isolator-based sterile filling line with lyophilization and several related infrastructural upgrades.